Dec 9, 2019 8:45 am EST Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
Nov 12, 2019 4:30 pm EST Abeona Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates
Oct 21, 2019 9:15 am EDT Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress
Oct 15, 2019 9:15 am EDT Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
Sep 23, 2019 8:45 am EDT Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa
Aug 9, 2019 4:15 pm EDT Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates
Jul 25, 2019 9:15 am EDT Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA
Jun 26, 2019 8:00 am EDT Abeona Therapeutics Appoints Dr. Victor Paulus Senior Vice President of Regulatory Affairs
Jun 18, 2019 8:29 am EDT Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease
